Movano Health Welcomes Dr. Shaheen Wirk to its Board of Directors
Movano Health (Nasdaq: MOVE) has appointed Dr. Shaheen Wirk to its Board of Directors. Dr. Wirk brings over 20 years of investment experience in life science companies and is the founder and Chief Investment Officer of Palkon Capital Management. This appointment follows Movano's recent FDA 510(k) clearance for the pulse oximeter in its EvieMED Ring.
The FDA clearance positions Movano to pursue multi-billion dollar opportunities in health monitoring solutions, particularly in clinical trials, post-clinical trial management, and remote patient monitoring. The company's first product, the Evie Ring wellness device, is currently available in the market through eviering.com.
Dr. Wirk's extensive background includes founding Blue Cotinga advisory firm and serving on boards including Tvardi Therapeutics. He holds M.D., M.B.A., and B.S. degrees from Duke University and completed research training in oncology and trauma surgery at prestigious institutions.
Movano Health (Nasdaq: MOVE) ha nominato il Dr. Shaheen Wirk nel suo Consiglio di Amministrazione. Il Dr. Wirk porta con sé oltre 20 anni di esperienza negli investimenti in aziende di scienze della vita ed è il fondatore e Chief Investment Officer di Palkon Capital Management. Questa nomina segue il recente nulla osta FDA 510(k) di Movano per il pulsossimetro nel suo EvieMED Ring.
Il nulla osta della FDA posiziona Movano per perseguire opportunità da miliardi di dollari nelle soluzioni di monitoraggio della salute, in particolare negli studi clinici, nella gestione post-studio clinico e nel monitoraggio remoto dei pazienti. Il primo prodotto dell'azienda, il dispositivo wellness Evie Ring, è attualmente disponibile sul mercato tramite eviering.com.
Il vasto background del Dr. Wirk include la fondazione della società di consulenza Blue Cotinga e il servizio in vari consigli di amministrazione, tra cui quello di Tvardi Therapeutics. Ha conseguito il Dottore di Medicina, il Master in Amministrazione Aziendale e la laurea in Scienze presso l'Università di Duke e ha completato un tirocinio di ricerca in oncologia e chirurgia traumatologica presso istituzioni prestigiose.
Movano Health (Nasdaq: MOVE) ha nombrado al Dr. Shaheen Wirk en su Junta Directiva. El Dr. Wirk aporta más de 20 años de experiencia en inversiones en empresas de ciencias de la vida y es el fundador y Director de Inversiones de Palkon Capital Management. Esta designación sigue a la reciente aprobación de la FDA 510(k) de Movano para el pulsioxímetro en su EvieMED Ring.
La aprobación de la FDA posiciona a Movano para perseguir oportunidades de miles de millones de dólares en soluciones de monitoreo de salud, particularmente en ensayos clínicos, gestión post-clínica y monitoreo remoto de pacientes. El primer producto de la compañía, el dispositivo de bienestar Evie Ring, está actualmente disponible en el mercado a través de eviering.com.
El extenso currículum del Dr. Wirk incluye la fundación de la firma de asesoría Blue Cotinga y el servicio en juntas, incluidas Tvardi Therapeutics. Posee títulos de M.D., M.B.A. y B.S. de la Universidad de Duke y completó su formación investigadora en oncología y cirugía de trauma en instituciones de prestigio.
Movano Health (Nasdaq: MOVE)는 Dr. Shaheen Wirk를 이사회에 임명했습니다. Dr. Wirk는 생명 과학 회사에 대한 20년 이상의 투자 경험을 가지고 있으며 Palkon Capital Management의 설립자이자 최고 투자 책임자입니다. 이번 임명은 Movano의 EvieMED 링에 대한 최근 FDA 510(k) 승인에 이어 이루어졌습니다.
FDA 승인은 Movano가 건강 모니터링 솔루션에서 수십억 달러 규모의 기회를 추구할 수 있도록 합니다. 특히 임상 시험, 임상 시험 후 관리 및 원격 환자 모니터링에서 그렇습니다. 회사의 첫 번째 제품인 Evie Ring 웰니스 장치는 현재 eviering.com을 통해 시장에서 구매할 수 있습니다.
Dr. Wirk는 Blue Cotinga 자문 회사를 설립하고 Tvardi Therapeutics를 포함한 여러 이사회에서 활동한 광범위한 배경을 가지고 있습니다. 그는 듀크 대학교에서 M.D., M.B.A., B.S. 학위를 취득했으며, 유명한 기관에서 종양학 및 외상 수술 연구 교육을 완료했습니다.
Movano Health (Nasdaq: MOVE) a nommé Dr. Shaheen Wirk au sein de son Conseil d'Administration. Dr. Wirk possède plus de 20 ans d'expérience dans les investissements dans des entreprises de sciences de la vie et est le fondateur et directeur des investissements de Palkon Capital Management. Cette nomination fait suite à l'agrément récent de la FDA 510(k) de Movano pour le puls oximètre de son EvieMED Ring.
L'agrément de la FDA positionne Movano pour poursuivre des opportunités de plusieurs milliards de dollars dans les solutions de surveillance de la santé, notamment dans les essais cliniques, la gestion post-essai clinique et la surveillance à distance des patients. Le premier produit de l'entreprise, le dispositif de bien-être Evie Ring, est actuellement disponible sur le marché via eviering.com.
Le parcours vaste du Dr. Wirk inclut la création de la société de conseil Blue Cotinga et la participation à des conseils d'administration, dont celui de Tvardi Therapeutics. Il détient des diplômes de M.D., M.B.A. et B.S. de l'Université de Duke et a terminé une formation de recherche en oncologie et en chirurgie traumatique dans des institutions prestigieuses.
Movano Health (Nasdaq: MOVE) hat Dr. Shaheen Wirk in seinen Vorstand berufen. Dr. Wirk bringt über 20 Jahre Erfahrung im Investmentbereich von Unternehmen der Lebenswissenschaften mit und ist Gründer sowie Chief Investment Officer von Palkon Capital Management. Diese Ernennung folgt auf die kürzliche FDA 510(k) Freigabe für den Puls-Oximeter im EvieMED Ring.
Die FDA-Freigabe positioniert Movano dazu, Chancen in Milliardenhöhe im Bereich der Gesundheitsüberwachung zu verfolgen, insbesondere in klinischen Studien, im Management nach klinischen Studien und in der Fernüberwachung von Patienten. Das erste Produkt des Unternehmens, das Evie Ring Wellness-Gerät, ist derzeit über eviering.com auf dem Markt erhältlich.
Dr. Wirk hat einen umfangreichen Hintergrund, der die Gründung der Beratungsfirma Blue Cotinga sowie die Mitgliedschaft in Vorständen, darunter Tvardi Therapeutics, umfasst. Er hat einen M.D., M.B.A. und B.S. Titel von der Duke University und hat eine Forschungsausbildung in Onkologie und Traumachirurgie an renommierten Institutionen abgeschlossen.
- Recent FDA 510(k) clearance for EvieMED Ring's pulse oximeter
- Access to multi-billion dollar market opportunities in health monitoring
- Addition of board member with 20+ years of healthcare investment experience
- None.
With over 20 years of investment experience in public and private life science companies, Dr. Wirk is the founder and Chief Investment Officer of Palkon Capital Management, a healthcare dedicated investment firm launched in partnership with Julian Robertson and Tiger Management. Formerly, Dr. Wirk was a senior analyst at Bridger Capital. He is the founder of the advisory firm Blue Cotinga and was an early employee at MercuryMD, which was successfully acquired by the Thomson Corp. He currently serves on several boards and associations including Tvardi Therapeutics and the Duke University School of Medicine's Medical Alumni Council, the leadership group for the Medical Alumni Association.
"It's an exciting time for Movano in driving healthcare innovation, and they are on the cusp of transforming the delivery of healthcare data," said Dr. Wirk. "The recent FDA approval of the EvieMED Ring allows Movano and its partners to remotely and accurately collect patient-specific key data while enabling more robust clinical development programs and the realization of remote patient monitoring solutions. I am honored to collaborate with Movano to achieve these goals."
Movano Health announced last month that it had received
"We are at a critical juncture in the evolution of our organization as we continue to innovate at the intersection of consumer wearable and medical device," said John Mastrototaro, President and CEO of Movano Health. "Dr. Wirk is a visionary in the healthcare space and has a wealth of investment experience with both private and public companies and we're excited to have him join the Movano Board of Directors."
Dr. Wirk completed research training programs in oncology and trauma surgery at the University of Texas MD Anderson Cancer Center, Rabin Medical Center through the National Institutes of Health Fogarty International Center, and Duke University Medical Center. Dr. Wirk earned his M.D., M.B.A., and B.S. degrees from Duke University.
About Movano Health
Founded in 2018, Movano Inc. (Nasdaq: MOVE) dba Movano Health is developing a suite of purpose-driven healthcare solutions to bring medical-grade data to the forefront of wearables. Featuring modern and flexible form factors, Movano Health's devices offer an innovative approach to delivering trusted data to both customers and enterprises, capturing a comprehensive picture of an individual's health data and uniquely translating it into personalized and intelligent insights.
Movano Health's proprietary technologies and wearable medical device solutions will soon enable the use of data as a tool to proactively monitor and manage health outcomes across a number of patient populations that exist in healthcare. For more information on Movano Health, visit https://movanohealth.com/.
Forward Looking Statements
This press release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding plans with respect to the commercial launches of the Evie Ring and EvieMED; our expectations regarding potential commercial opportunities; planned cost-cutting initiatives; anticipated FDA clearance decisions with respect to our products; expected future operating results; product development and features, product releases, clinical trials and regulatory initiatives; our strategies, positioning and expectations for future events or performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission, including under the caption "Risk Factors." Any forward-looking statement in this release speaks only as of the date of this release. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
View original content to download multimedia:https://www.prnewswire.com/news-releases/movano-health-welcomes-dr-shaheen-wirk-to-its-board-of-directors-302340968.html
SOURCE Movano
FAQ
What is the significance of Movano Health's (MOVE) recent FDA clearance for the EvieMED Ring?
How will Dr. Shaheen Wirk's appointment impact Movano Health (MOVE)?
What are the current products offered by Movano Health (MOVE)?
What market opportunities does Movano Health (MOVE) target with the EvieMED Ring?
